Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy
The augmentation of [ Lu]Lu-PSMA-617 radioligand therapy by alpha emitting [ Ac]Ac-PSMA-617, known as the tandem therapy concept, is a promising escalating treatment option in advanced mCRPC. In this study, we evaluated the value of [ F]FDG PET/CT-derived molecular imaging biomarkers for predicting...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-10, Vol.16 (20), p.3532 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 20 |
| container_start_page | 3532 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Burgard, Caroline Khreish, Fadi Dahlmanns, Lukas Blickle, Arne Bastian, Moritz B Speicher, Tilman Maus, Stephan Schaefer-Schuler, Andrea Bartholomä, Mark Petto, Sven Ezziddin, Samer Rosar, Florian |
| description | The augmentation of [
Lu]Lu-PSMA-617 radioligand therapy by alpha emitting [
Ac]Ac-PSMA-617, known as the tandem therapy concept, is a promising escalating treatment option in advanced mCRPC. In this study, we evaluated the value of [
F]FDG PET/CT-derived molecular imaging biomarkers for predicting response and outcome to PSMA tandem RLT in
= 33 patients with insufficient response on [
Lu]Lu-PSMA-617 monotherapy.
Six different molecular imaging parameters at baseline, i.e., before initiation of PSMA tandem RLT with respect to SUV
, SUV
, SUV
, SUV
, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were tested for association with response and overall survival (OS).
After the initiation of augmentation, 24.2% of patients with a previously insufficient response experienced partial remission, and 39.4% experienced stable disease. The median OS was 7 months (95% CI: 4-11 months). None of the tested parameters were able to predict the response (all
> 0.529). In contrast, the [
F]FDG PET/CT-derived whole-body molecular imaging parameter TLG was significantly (
= 0.029) associated with OS of patients undergoing [
Ac]Ac-PSMA-617 augmented [
Lu]Lu-PSMA-617 RLT after insufficient response to [
Lu]Lu-PSMA-617 monotherapy.
Implementing [
F]FDG PET/CT in the management of PSMA-RLT in clinical practice may contribute to outcome prediction and provide a route to more individualized management in mCRPC. |
| doi_str_mv | 10.3390/cancers16203532 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11506772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120549626</sourcerecordid><originalsourceid>FETCH-LOGICAL-c232t-2c902930fa2216d3cb11dbe01a3fe9b20bd44221bc517d996e6a8c20a283bcb73</originalsourceid><addsrcrecordid>eNpdUl1r2zAUNWNjLV2f9zYu7GV78KKPWI73Mty0SQsuNa3LHkowsiQ76mwrk2JDfvf-QFXShW56keCce865ujcIPmL0jdIETQTvhbIOM4JoRMmb4JigmISMJdO3r95Hwalzj8gfSnHM4vfBEU2mEWOEHQd_0p63O6cdmBquTavE0HILVx1vdN_AmTYdt7-8C5wrq0clobamgwfAM1isFudLyC-KybwA3UM3v83n3-Hn2suEZ0buoDBb3kKmnDY9LNudMHuvL0W2_Aq5VVKLrYObUVnetnA32FGPvsKL5XyrVe_B-14q25jnNA9ASASpWKUizO-u05DhOEyHpvNEn8yHimPIhlU2HGC45VKbVje8l1Csvc9m9yF4V_PWqdOX-yS4X1wU88swu1lezdMsFISSbUhEgkhCUc0JwUxSUWEsK4Uwp7VKKoIqOZ16qBIRjmWSMMX4TBDEyYxWoorpSfBjr7sZqk5J4VP6NsuN1f5Pd6XhuvwX6fW6bMxYYhwhFsfEK3x-UbDm96Dctnw0g_UTcyXFBEXTxA_RsyZ7lrDGOavqgwVG5fOmlP9tiq_49DrZgf93L-gTig25kw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120549626</pqid></control><display><type>article</type><title>Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Burgard, Caroline ; Khreish, Fadi ; Dahlmanns, Lukas ; Blickle, Arne ; Bastian, Moritz B ; Speicher, Tilman ; Maus, Stephan ; Schaefer-Schuler, Andrea ; Bartholomä, Mark ; Petto, Sven ; Ezziddin, Samer ; Rosar, Florian</creator><creatorcontrib>Burgard, Caroline ; Khreish, Fadi ; Dahlmanns, Lukas ; Blickle, Arne ; Bastian, Moritz B ; Speicher, Tilman ; Maus, Stephan ; Schaefer-Schuler, Andrea ; Bartholomä, Mark ; Petto, Sven ; Ezziddin, Samer ; Rosar, Florian</creatorcontrib><description>The augmentation of [
Lu]Lu-PSMA-617 radioligand therapy by alpha emitting [
Ac]Ac-PSMA-617, known as the tandem therapy concept, is a promising escalating treatment option in advanced mCRPC. In this study, we evaluated the value of [
F]FDG PET/CT-derived molecular imaging biomarkers for predicting response and outcome to PSMA tandem RLT in
= 33 patients with insufficient response on [
Lu]Lu-PSMA-617 monotherapy.
Six different molecular imaging parameters at baseline, i.e., before initiation of PSMA tandem RLT with respect to SUV
, SUV
, SUV
, SUV
, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were tested for association with response and overall survival (OS).
After the initiation of augmentation, 24.2% of patients with a previously insufficient response experienced partial remission, and 39.4% experienced stable disease. The median OS was 7 months (95% CI: 4-11 months). None of the tested parameters were able to predict the response (all
> 0.529). In contrast, the [
F]FDG PET/CT-derived whole-body molecular imaging parameter TLG was significantly (
= 0.029) associated with OS of patients undergoing [
Ac]Ac-PSMA-617 augmented [
Lu]Lu-PSMA-617 RLT after insufficient response to [
Lu]Lu-PSMA-617 monotherapy.
Implementing [
F]FDG PET/CT in the management of PSMA-RLT in clinical practice may contribute to outcome prediction and provide a route to more individualized management in mCRPC.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16203532</identifier><identifier>PMID: 39456626</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Androgens ; Antigens ; Biomarkers ; Cancer therapies ; Castration ; Computed tomography ; FDA approval ; Glycolysis ; Medical imaging ; Medical prognosis ; Metastases ; Patients ; Positron emission tomography ; Prostate cancer ; Statistical analysis ; Survival ; Tomography</subject><ispartof>Cancers, 2024-10, Vol.16 (20), p.3532</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c232t-2c902930fa2216d3cb11dbe01a3fe9b20bd44221bc517d996e6a8c20a283bcb73</cites><orcidid>0000-0003-1679-8080 ; 0000-0002-0361-2833 ; 0000-0002-2985-4099 ; 0000-0003-1522-8860 ; 0000-0003-4110-3375 ; 0009-0008-2106-9548</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506772/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506772/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39456626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burgard, Caroline</creatorcontrib><creatorcontrib>Khreish, Fadi</creatorcontrib><creatorcontrib>Dahlmanns, Lukas</creatorcontrib><creatorcontrib>Blickle, Arne</creatorcontrib><creatorcontrib>Bastian, Moritz B</creatorcontrib><creatorcontrib>Speicher, Tilman</creatorcontrib><creatorcontrib>Maus, Stephan</creatorcontrib><creatorcontrib>Schaefer-Schuler, Andrea</creatorcontrib><creatorcontrib>Bartholomä, Mark</creatorcontrib><creatorcontrib>Petto, Sven</creatorcontrib><creatorcontrib>Ezziddin, Samer</creatorcontrib><creatorcontrib>Rosar, Florian</creatorcontrib><title>Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>The augmentation of [
Lu]Lu-PSMA-617 radioligand therapy by alpha emitting [
Ac]Ac-PSMA-617, known as the tandem therapy concept, is a promising escalating treatment option in advanced mCRPC. In this study, we evaluated the value of [
F]FDG PET/CT-derived molecular imaging biomarkers for predicting response and outcome to PSMA tandem RLT in
= 33 patients with insufficient response on [
Lu]Lu-PSMA-617 monotherapy.
Six different molecular imaging parameters at baseline, i.e., before initiation of PSMA tandem RLT with respect to SUV
, SUV
, SUV
, SUV
, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were tested for association with response and overall survival (OS).
After the initiation of augmentation, 24.2% of patients with a previously insufficient response experienced partial remission, and 39.4% experienced stable disease. The median OS was 7 months (95% CI: 4-11 months). None of the tested parameters were able to predict the response (all
> 0.529). In contrast, the [
F]FDG PET/CT-derived whole-body molecular imaging parameter TLG was significantly (
= 0.029) associated with OS of patients undergoing [
Ac]Ac-PSMA-617 augmented [
Lu]Lu-PSMA-617 RLT after insufficient response to [
Lu]Lu-PSMA-617 monotherapy.
Implementing [
F]FDG PET/CT in the management of PSMA-RLT in clinical practice may contribute to outcome prediction and provide a route to more individualized management in mCRPC.</description><subject>Androgens</subject><subject>Antigens</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Castration</subject><subject>Computed tomography</subject><subject>FDA approval</subject><subject>Glycolysis</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Patients</subject><subject>Positron emission tomography</subject><subject>Prostate cancer</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>Tomography</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUl1r2zAUNWNjLV2f9zYu7GV78KKPWI73Mty0SQsuNa3LHkowsiQ76mwrk2JDfvf-QFXShW56keCce865ujcIPmL0jdIETQTvhbIOM4JoRMmb4JigmISMJdO3r95Hwalzj8gfSnHM4vfBEU2mEWOEHQd_0p63O6cdmBquTavE0HILVx1vdN_AmTYdt7-8C5wrq0clobamgwfAM1isFudLyC-KybwA3UM3v83n3-Hn2suEZ0buoDBb3kKmnDY9LNudMHuvL0W2_Aq5VVKLrYObUVnetnA32FGPvsKL5XyrVe_B-14q25jnNA9ASASpWKUizO-u05DhOEyHpvNEn8yHimPIhlU2HGC45VKbVje8l1Csvc9m9yF4V_PWqdOX-yS4X1wU88swu1lezdMsFISSbUhEgkhCUc0JwUxSUWEsK4Uwp7VKKoIqOZ16qBIRjmWSMMX4TBDEyYxWoorpSfBjr7sZqk5J4VP6NsuN1f5Pd6XhuvwX6fW6bMxYYhwhFsfEK3x-UbDm96Dctnw0g_UTcyXFBEXTxA_RsyZ7lrDGOavqgwVG5fOmlP9tiq_49DrZgf93L-gTig25kw</recordid><startdate>20241019</startdate><enddate>20241019</enddate><creator>Burgard, Caroline</creator><creator>Khreish, Fadi</creator><creator>Dahlmanns, Lukas</creator><creator>Blickle, Arne</creator><creator>Bastian, Moritz B</creator><creator>Speicher, Tilman</creator><creator>Maus, Stephan</creator><creator>Schaefer-Schuler, Andrea</creator><creator>Bartholomä, Mark</creator><creator>Petto, Sven</creator><creator>Ezziddin, Samer</creator><creator>Rosar, Florian</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1679-8080</orcidid><orcidid>https://orcid.org/0000-0002-0361-2833</orcidid><orcidid>https://orcid.org/0000-0002-2985-4099</orcidid><orcidid>https://orcid.org/0000-0003-1522-8860</orcidid><orcidid>https://orcid.org/0000-0003-4110-3375</orcidid><orcidid>https://orcid.org/0009-0008-2106-9548</orcidid></search><sort><creationdate>20241019</creationdate><title>Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy</title><author>Burgard, Caroline ; Khreish, Fadi ; Dahlmanns, Lukas ; Blickle, Arne ; Bastian, Moritz B ; Speicher, Tilman ; Maus, Stephan ; Schaefer-Schuler, Andrea ; Bartholomä, Mark ; Petto, Sven ; Ezziddin, Samer ; Rosar, Florian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c232t-2c902930fa2216d3cb11dbe01a3fe9b20bd44221bc517d996e6a8c20a283bcb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Androgens</topic><topic>Antigens</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Castration</topic><topic>Computed tomography</topic><topic>FDA approval</topic><topic>Glycolysis</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Patients</topic><topic>Positron emission tomography</topic><topic>Prostate cancer</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burgard, Caroline</creatorcontrib><creatorcontrib>Khreish, Fadi</creatorcontrib><creatorcontrib>Dahlmanns, Lukas</creatorcontrib><creatorcontrib>Blickle, Arne</creatorcontrib><creatorcontrib>Bastian, Moritz B</creatorcontrib><creatorcontrib>Speicher, Tilman</creatorcontrib><creatorcontrib>Maus, Stephan</creatorcontrib><creatorcontrib>Schaefer-Schuler, Andrea</creatorcontrib><creatorcontrib>Bartholomä, Mark</creatorcontrib><creatorcontrib>Petto, Sven</creatorcontrib><creatorcontrib>Ezziddin, Samer</creatorcontrib><creatorcontrib>Rosar, Florian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burgard, Caroline</au><au>Khreish, Fadi</au><au>Dahlmanns, Lukas</au><au>Blickle, Arne</au><au>Bastian, Moritz B</au><au>Speicher, Tilman</au><au>Maus, Stephan</au><au>Schaefer-Schuler, Andrea</au><au>Bartholomä, Mark</au><au>Petto, Sven</au><au>Ezziddin, Samer</au><au>Rosar, Florian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-10-19</date><risdate>2024</risdate><volume>16</volume><issue>20</issue><spage>3532</spage><pages>3532-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The augmentation of [
Lu]Lu-PSMA-617 radioligand therapy by alpha emitting [
Ac]Ac-PSMA-617, known as the tandem therapy concept, is a promising escalating treatment option in advanced mCRPC. In this study, we evaluated the value of [
F]FDG PET/CT-derived molecular imaging biomarkers for predicting response and outcome to PSMA tandem RLT in
= 33 patients with insufficient response on [
Lu]Lu-PSMA-617 monotherapy.
Six different molecular imaging parameters at baseline, i.e., before initiation of PSMA tandem RLT with respect to SUV
, SUV
, SUV
, SUV
, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were tested for association with response and overall survival (OS).
After the initiation of augmentation, 24.2% of patients with a previously insufficient response experienced partial remission, and 39.4% experienced stable disease. The median OS was 7 months (95% CI: 4-11 months). None of the tested parameters were able to predict the response (all
> 0.529). In contrast, the [
F]FDG PET/CT-derived whole-body molecular imaging parameter TLG was significantly (
= 0.029) associated with OS of patients undergoing [
Ac]Ac-PSMA-617 augmented [
Lu]Lu-PSMA-617 RLT after insufficient response to [
Lu]Lu-PSMA-617 monotherapy.
Implementing [
F]FDG PET/CT in the management of PSMA-RLT in clinical practice may contribute to outcome prediction and provide a route to more individualized management in mCRPC.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39456626</pmid><doi>10.3390/cancers16203532</doi><orcidid>https://orcid.org/0000-0003-1679-8080</orcidid><orcidid>https://orcid.org/0000-0002-0361-2833</orcidid><orcidid>https://orcid.org/0000-0002-2985-4099</orcidid><orcidid>https://orcid.org/0000-0003-1522-8860</orcidid><orcidid>https://orcid.org/0000-0003-4110-3375</orcidid><orcidid>https://orcid.org/0009-0008-2106-9548</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-10, Vol.16 (20), p.3532 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11506772 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Androgens Antigens Biomarkers Cancer therapies Castration Computed tomography FDA approval Glycolysis Medical imaging Medical prognosis Metastases Patients Positron emission tomography Prostate cancer Statistical analysis Survival Tomography |
| title | Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T03%3A52%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20Molecular%20Imaging%20Biomarkers%20Derived%20from%20%5B%2018%20F%5DFDG%20PET/CT%20in%20mCRPC:%20Whole-Body%20Total%20Lesion%20Glycolysis%20(TLG)%20Predicts%20Overall%20Survival%20in%20Patients%20Undergoing%20%5B%20225%20Ac%5DAc-PSMA-617-Augmented%20%5B%20177%20Lu%5DLu-PSMA-617%20Radioligand%20Therapy&rft.jtitle=Cancers&rft.au=Burgard,%20Caroline&rft.date=2024-10-19&rft.volume=16&rft.issue=20&rft.spage=3532&rft.pages=3532-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16203532&rft_dat=%3Cproquest_pubme%3E3120549626%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3120549626&rft_id=info:pmid/39456626&rfr_iscdi=true |